Results 31 to 40 of about 4,498 (182)

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

Lack of antiviral activity of darunavir against SARS-CoV-2

International Journal of Infectious Diseases, 2020
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are ...
Sandra De Meyer, Denisa Bojkova, Jindrich Cinatl, Ellen Van Damme, Christophe Buyck, Marnix Van Loock, Brian Woodfall, Sandra Ciesek   +7 more
doaj   +1 more source

Characteristics and management of low‐level viraemia in people living with HIV in a resource‐limited setting: A multicentre retrospective study in Greece

HIV Medicine, EarlyView.
Abstract Objectives Low‐level viraemia (LLV) persists in some people living with HIV despite antiretroviral therapy, raising concerns about virologic failure. We assessed the characteristics, management and outcomes of LLV in Greece, where next‐generation sequencing, therapeutic drug monitoring and electronic adherence monitoring are unavailable ...
Lydia Leonidou, Giota Lourida, Konstantinos Protopapas, Charalampos D. Moschopoulos, Dimitrios Zoulas, Charisis Totsikas, Dimitrios Basoulis, Elpida Mastrogianni, Apostolos Beloukas, Maria Lagadinou, Markos Marangos, Vasileios Papastamopoulos, Antonios Papadopoulos, Mina Psichogiou   +13 more
wiley   +1 more source

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Pharmaceutics, 2023
Background: The clinical outcomes of antiretroviral drugs may be modified through drug interactions; thus, it is important to update the drug interactions in people living with HIV (PLHIV). Aim: To update clinically relevant drug interactions in PLHIV on
Pedro Amariles, Mónica Rivera-Cadavid, Mauricio Ceballos   +2 more
doaj   +1 more source

Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co‐Infected With HIV

Tropical Medicine &International Health, EarlyView.
ABSTRACT Background HIV co‐infection affects host responses and pharmacokinetics (PK) of tuberculosis (TB) treatment. This study assessed the PK of first‐line anti‐TB drugs and clinical outcomes in patients with and without HIV co‐infection. Methods In this prospective observational study, 61 adults with sputum‐positive pulmonary TB, either confirmed ...
Aung Pyae Phyo, Richard M. Hoglund, Makoto Saito, Sein Sein Thi, Lei Lei Swe, Palang Chotsiri, Htet Ko Ko Aung, Win Pa Pa Tun, Banyar Maung Maung, Chanapat Pateekham, Wanitda Watthanaworawit, Gornpan Gornsawun, Nicholas J. White, Francois Nosten, Joel Tarning   +14 more
wiley   +1 more source

Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

BMC Nephrology, 2020
Background Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).
José Ramón Santos, Ana Merino, Walter E. Haefeli, Cristina Miranda, Marisol Prats, Ioana Bancu, Lucía Bailón, José Moltó   +7 more
doaj   +1 more source

Mapping opioid exposure through prescription data and postmortem analysis of opioid drugs in multiple tissues

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2624-2635, August 2026.
Background and Purpose Although opioids are central to end of life (EoL) care, tissue‐level opioid exposure remains poorly understood. The objective of this study was to characterize the relationship between prescription‐derived morphine equivalent daily dose (MEDD) and measured morphine concentrations across multiple organs.
Niamh Higgins, Alan Wells, Nimish Patel, Nicole Muttera, Mattia Trunfio, Alessandra Manca, Amedeo De Nicolò, Micol Ferrara, Stefano Bonora, Jessica Cusato, Alice Palermiti, Antonio D'Avolio, Marissa Borochoff, Patricia K. Riggs, Elizabeth Hastie, Rabia S. Atayee, Stephanie Solso, Cheryl Dullano, Vanessa Gomez‐Moreno, Tara Tenenbaum, Robert Deiss, Davey M. Smith, Antoine Chaillon, Sara Gianella   +23 more
wiley   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS

HIV/AIDS: Research and Palliative Care, 2016
Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is
Navarro J, Curran A
doaj  

Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

Drugs in Context, 2019
The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to ...
Melissa E Badowski, Bradley Burton, Kristy M Shaeer, John Dicristofano   +3 more
doaj   +1 more source